Unnamed: 0,title,date,stock,sentiment
63742.0,"Alnylam Say Lumasiran Met Primary Efficacy Endpoint of 24-hour Urinary Oxalate Reduction from Month 3 to 6 Relative to Placebo, All Tested Secondary Endpoints",2020-06-07 08:49:00-04:00,ALNY,neutral
63743.0,"UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $122",2020-05-28 09:05:00-04:00,ALNY,neutral
63744.0,Alnylam Announces FDA Has Granted Priority Review Of Lumasiran New Drug Application For Primary Hyperoxaluria Type 1,2020-05-26 07:01:00-04:00,ALNY,positive
63745.0,"Hedge Fund Duquesne 13F Shows Increased Stakes In Facebook, Alibaba, Netflix, Amazon, Google, Alnylman",2020-05-15 14:43:00-04:00,ALNY,positive
63746.0,"RBC Capital Initiates Coverage On Alnylam Pharmaceuticals with Sector Perform Rating, Announces Price Target of $150",2020-05-13 05:06:00-04:00,ALNY,neutral
63747.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $171",2020-05-07 12:53:00-04:00,ALNY,neutral
63748.0,"Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $156",2020-05-07 10:43:00-04:00,ALNY,negative
63749.0,"Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $162",2020-05-07 10:14:00-04:00,ALNY,neutral
63750.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ALNY,negative
63751.0,"Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $162",2020-05-07 07:31:00-04:00,ALNY,negative
63752.0,"JP Morgan Downgrades Alnylam Pharmaceuticals to Neutral, Raises Price Target of $137",2020-05-07 06:11:00-04:00,ALNY,positive
63753.0,"Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target of $160",2020-05-06 13:44:00-04:00,ALNY,neutral
63754.0,Alnylam Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-06 11:34:00-04:00,ALNY,positive
63755.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,ALNY,neutral
63756.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,ALNY,positive
63757.0,Alnylam Cuts FY20 ONPATTRO Sales Guidance From $285M-$315M To $270M-$300M,2020-05-06 08:08:00-04:00,ALNY,negative
63758.0,"Alnylam Pharmaceuticals Q1 Adj. EPS $(1.520) Beats $(1.890) Estimate, Sales $99.476M Beat $91.560M Estimate",2020-05-06 08:08:00-04:00,ALNY,neutral
63759.0,"Vir And Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 For Treatment Of Coronavirus COVID-19",2020-05-04 07:32:00-04:00,ALNY,neutral
63760.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ALNY,neutral
63761.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,ALNY,neutral
63762.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,ALNY,neutral
63763.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,ALNY,negative
63764.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-21 10:30:00-04:00,ALNY,neutral
63765.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,ALNY,neutral
63766.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,ALNY,neutral
63767.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,ALNY,neutral
63768.0,"Nomura Maintains Reduce on Alnylam Pharmaceuticals, Lowers Price Target to $74",2020-04-14 08:05:00-04:00,ALNY,negative
63769.0,Alnylam Receives Fast Track Designation For Vutrisiran For The Treatment Of The Polyneuropathy Of hATTR Amyloidosis,2020-04-14 07:03:00-04:00,ALNY,neutral
63770.0,Blackstone And Alnylam Enter Into $2B Strategic Financing Collaboration To 'Accelerate the Advancement of RNAi Therapeutics',2020-04-13 07:35:00-04:00,ALNY,neutral
63771.0,Alnylam Pharmaceuticals shares are trading higher following an announcement that Blackstone invested $2B into the company.,2020-04-13 07:00:00-04:00,ALNY,positive
63772.0,"Blackstone Invests $2B in Alnylam Pharma, According to the Wall Street Journal",2020-04-13 06:51:00-04:00,ALNY,neutral
63773.0,"The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates",2020-04-12 10:05:00-04:00,ALNY,neutral
63774.0,Alnylam Completes Rolling Submission Of New Drug Application To The FDA And Submits Marketing Authorization Application To The European Medicines Agency For Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1,2020-04-07 07:14:00-04:00,ALNY,neutral
63775.0,Alnylam and Dicerna Form a RNAi Therapeutics Collaboration on Alpha-1  Antitrypsin Deficiency-Associated Liver Disease,2020-04-06 07:12:00-04:00,ALNY,neutral
63776.0,"The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation",2020-04-02 07:57:00-04:00,ALNY,positive
63777.0,"Vir Biotech, Alnylam Pharma To Expand Multi-Target Existing Collaboration For Development, Commercialization Of RNAi Therapeutics, Including Coronavirus Infection",2020-04-02 07:05:00-04:00,ALNY,positive
63778.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,ALNY,positive
63779.0,Alnylam Pharmaceuticals And Gen Sign Distribution Agreement In Turkey For ONPATTRO 'Gene-Silencing' RNAi Therapeutic,2020-03-25 06:05:00-04:00,ALNY,positive
63780.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,ALNY,negative
63781.0,"Berenberg Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces $200 Price Target",2020-03-19 11:26:00-04:00,ALNY,neutral
63782.0,"Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership",2020-03-04 08:40:00-05:00,ALNY,neutral
63783.0,"Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 4, 2020: JWN, VIR, CMG, AHPI, GNMK",2020-03-04 08:04:00-05:00,ALNY,positive
63784.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,ALNY,negative
63785.0,"Vir and Alnylam Expand Collaboration To Advance RNAi Therapeutics For The Treatment Of Coronavirus Infection, Including COVID-19",2020-03-04 07:03:00-05:00,ALNY,positive
63786.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,ALNY,positive
63787.0,Alnylam Pharma Reports ONPATTRO Approved In Brazil For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy,2020-02-26 08:12:00-05:00,ALNY,positive
63788.0,Alnylam Completes Enrollment Of HELIOS-A Phase 3 Study Of Vutrisiran For The Treatment Of hATTR Amyloidosis With Polyneuropathy,2020-02-18 07:24:00-05:00,ALNY,neutral
63789.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ALNY,negative
63790.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,ALNY,positive
63791.0,"Nomura Maintains Reduce on Alnylam Pharmaceuticals, Raises Price Target to $75",2020-02-11 08:58:00-05:00,ALNY,neutral
63792.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,ALNY,positive
63793.0,Stocks That Hit 52-Week Highs On Monday,2020-02-10 10:25:00-05:00,ALNY,neutral
63794.0,"Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $148",2020-02-07 09:29:00-05:00,ALNY,negative
63795.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,ALNY,negative
63796.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,ALNY,neutral
63797.0,Alnylam Sees FY20 ONPATTRO Net Product Revenues $285M-$315M,2020-02-06 08:19:00-05:00,ALNY,neutral
63798.0,"Alnylam Pharmaceuticals Q4 EPS $(1.98) Beats $(2.23) Estimate, Sales $71.681M Miss $72M Estimate",2020-02-06 08:18:00-05:00,ALNY,negative
63799.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,ALNY,negative
63800.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,ALNY,neutral
63801.0,"Alnylam Reports Receives Positive CHMP Opinion For GIVLAARI For Acute Hepatic Porphyria In Adults, Adolescents",2020-01-31 06:06:00-05:00,ALNY,positive
63802.0,Alnylam Preliminary FY Global Net Product Revenue $166M vs $220.54M Est; Q4 Revenue $56M vs $71.48M Est,2020-01-12 19:09:00-05:00,ALNY,neutral
63803.0,Alnylam Initiates Rolling Submission of New Drug Application To FDA For Lumasiran For Treatment Of Primary Hyperoxaluria Type 1,2020-01-10 16:05:00-05:00,ALNY,neutral
63804.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,ALNY,neutral
63805.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,ALNY,neutral
63806.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,ALNY,neutral
63807.0,"Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $190",2019-12-19 07:48:00-05:00,ALNY,neutral
63808.0,10 Biggest Price Target Changes For Wednesday,2019-12-18 08:39:00-05:00,ALNY,neutral
63809.0,"Cantor Fitzgerald Reiterates Overweight on Alnylam Pharmaceuticals, Raises Price Target to $176",2019-12-18 07:46:00-05:00,ALNY,negative
63810.0,"Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $150",2019-12-17 08:57:00-05:00,ALNY,negative
63811.0,Alnylam Announces ILLUMINATE-A Phase 3 Study Of Lumasiran Met Primary And All Tested Secondary Endpoints,2019-12-17 07:01:00-05:00,ALNY,neutral
63812.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,ALNY,positive
63813.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,ALNY,positive
63814.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,ALNY,negative
63815.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,ALNY,neutral
63816.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,ALNY,negative
63817.0,Alnylam Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-11-26 11:32:00-05:00,ALNY,positive
63818.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,ALNY,neutral
63819.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,ALNY,positive
63820.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $143",2019-11-25 10:43:00-05:00,ALNY,neutral
63821.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,ALNY,neutral
63822.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,ALNY,neutral
63823.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More",2019-11-24 16:19:00-05:00,ALNY,positive
63824.0,Stocks That Hit 52-Week Highs On Friday,2019-11-22 10:17:00-05:00,ALNY,neutral
63825.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,ALNY,positive
63826.0,"UPDATE: Alnylam Reports Initiation Of HELIOS-B Phase 3 Study; Offers Initial Clinical Results With ALN-AAT02, ALN-HB02",2019-11-22 07:05:00-05:00,ALNY,neutral
63827.0,"Alnylam Offers 2020 Product, Pipeline Goals",2019-11-22 07:03:00-05:00,ALNY,neutral
63828.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $138",2019-11-21 10:30:00-05:00,ALNY,neutral
63829.0,"Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $141",2019-11-21 10:24:00-05:00,ALNY,negative
63830.0,"UPDATE: Cantor Says Is Looking Forward To Added Color At Alnylam's R&D Day Friday, Continues To Believe Co. Could Be $15B-$20B Co. Over Next 12-18 Months",2019-11-21 09:49:00-05:00,ALNY,neutral
63831.0,"Cantor Believes Alnylam Is In 'Breakout Mode,' Sees Recent Strength From 2 Factors: 1. Greater Confidence That RNAi Is A Real New Class Of Commercial Medicines, 2. Less Concern Pfizer's Tafamidis Will Take Meaningful Share From Onpattro Launch",2019-11-21 09:48:00-05:00,ALNY,positive
63832.0,10 Biggest Price Target Changes For Thursday,2019-11-21 08:31:00-05:00,ALNY,neutral
63833.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,ALNY,positive
63834.0,"Cantor Fitzgerald Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $159",2019-11-21 07:21:00-05:00,ALNY,negative
63835.0,"Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $131",2019-11-21 06:29:00-05:00,ALNY,negative
63836.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,ALNY,neutral
63837.0,"Alnylam Pharma Shares Resume Trade, Pullback From Session High, Still Up 7.3% For Session",2019-11-20 15:30:00-05:00,ALNY,positive
63838.0,Alnylam Pharma Shares To Resume Trade At 3:30 p.m. EST,2019-11-20 15:27:00-05:00,ALNY,positive
63839.0,Alnylam Pharmaceuticals Inc Prices Genetic Disorder Treatment Givlaari At $575K/Yr,2019-11-20 14:41:00-05:00,ALNY,negative
63840.0,"Ironwood Pharmaceuticals Shares Up 2.78% For The Session; NOTE: Co. Previously Entered Gastrointestinal Disease Education And Promotional Agreement With Alnylam Pharmaceuticals For Givlaari, Which Today Received FDA Approval",2019-11-20 14:24:00-05:00,ALNY,positive
63841.0,FDA PR Confirms Approval Of Alnylam's Givlaari For Treatment Of Adult Patients With Acute Hepatic Porphyria,2019-11-20 13:24:00-05:00,ALNY,positive
63842.0,FDA Granted Approval To Alnylam's Givlaari For Treatment Of Adult Patients With Acute Hepatic Porphyria,2019-11-20 12:40:00-05:00,ALNY,positive
63843.0,"Alnylam Pharmaceuticals Shares Halted, News Pending",2019-11-20 11:54:00-05:00,ALNY,positive
63844.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,ALNY,neutral
63845.0,"Benzinga's Top Upgrades, Downgrades For November 20, 2019",2019-11-20 09:37:00-05:00,ALNY,positive
63846.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,ALNY,positive
63847.0,"Oppenheimer Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces $128 Price Target",2019-11-20 06:27:00-05:00,ALNY,neutral
63848.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,ALNY,neutral
63849.0,The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down,2019-11-17 08:42:00-05:00,ALNY,neutral
63850.0,"Bank of America Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces $110 Price Target",2019-11-13 09:44:00-05:00,ALNY,neutral
63851.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,ALNY,positive
63852.0,"Alnylam Pharmaceuticals Q3 EPS $(1.5) Up From $(1.56) YoY, Sales $70.061M Up From $2.069M YoY",2019-10-31 09:35:00-04:00,ALNY,neutral
63853.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,ALNY,positive
63854.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,ALNY,neutral
63855.0,Alnylam Reports Filing For Marketing Authorization Of ONPATTRO For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy In Brazil,2019-10-10 07:33:00-04:00,ALNY,neutral
63856.0,Alnylam Pharmaceuticals Option Alert: Dec 20 $85 Calls at the Ask: 1000 @ $5.201 vs 55 OI; Earnings 11/6 Before Open [est] Ref=$80.8,2019-09-27 14:33:00-04:00,ALNY,positive
63857.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,ALNY,neutral
63858.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,ALNY,negative
63859.0,Alnylam Pharma Reports Initiated APOLLO-B Phase 3 Study Of Patisiran For Treatment Of Transthyretin Amyloidosis With Cardiomyopathy,2019-09-16 07:38:00-04:00,ALNY,neutral
63860.0,Alnylam Pharma Presents New Evidence Showing Significant Association Of V122I With Clinical Diagnosis Of Polyeuropathy,2019-09-13 07:31:00-04:00,ALNY,positive
63861.0,"UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $96",2019-09-04 07:10:00-04:00,ALNY,neutral
63862.0,"Cantor Fitzgerald On Alnylam Pharmaceuticals Also Notes 'If the ORION-9 and ORION-10 readouts expected this month also look clean, we think that overall ALNY shares may move 10-20% cumulatively based on these updates",2019-09-03 13:29:00-04:00,ALNY,positive
63863.0,"Cantor Fitzgerald Reiterates Overweight, $138 Tgt On Alnylam Pharma As Firm Notes Co's Partner Medicines Co. Presented ORION-11 Ph3 Data For Inclisiran And Firm Thinks 'the detailed ORION-11 data is supportive of ALNY platform efficacy and safety'",2019-09-03 13:29:00-04:00,ALNY,positive
63864.0,"Piper Jaffray Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $145",2019-09-03 07:00:00-04:00,ALNY,negative
63865.0,"The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight",2019-09-02 15:13:00-04:00,ALNY,neutral
63866.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,ALNY,negative
63867.0,"Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster",2019-08-20 17:35:00-04:00,ALNY,positive
63868.0,Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter US GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP),2019-08-13 07:31:00-04:00,ALNY,positive
63869.0,"Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $124",2019-08-07 08:25:00-04:00,ALNY,negative
63870.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,ALNY,neutral
63871.0,"Alnylam Pharmaceuticals Q2 Adj. EPS $(1.83) Beats $(1.86) Estimate, Sales $44.714M Miss $69.2M Estimate",2019-08-06 07:33:00-04:00,ALNY,negative
63872.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ALNY,positive
63873.0,"Alnylam Phamra Reports FDA Granted Priority Review Of Givosiran New Drug Application For Treatment Of Acute Hepatic Porphyria; PDUFA Date Set For Feb. 4, 2020",2019-08-05 16:01:00-04:00,ALNY,positive
63874.0,Alnylam Launches ONPATTRO For The Treatment Of Polyneuropathy In hATTR Amyloidosis RNAi Therapeutic,2019-07-23 07:13:00-04:00,ALNY,neutral
63875.0,Alnylam And 23andMe Collaborate On +MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis,2019-07-16 07:06:00-04:00,ALNY,positive
63876.0,Alnylam Pharma CFO Manmeet Soni To Resign; Jeff Poulton Named Replacement,2019-07-11 08:32:00-04:00,ALNY,negative
63877.0,"The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief",2019-07-03 07:31:00-04:00,ALNY,negative
63878.0,Alnylam Submits a Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria,2019-07-01 07:07:00-04:00,ALNY,neutral
63879.0,Alnylam Presents New ONPATTRO Results at the 2019 Peripheral Nerve Society Annual Meeting,2019-06-24 07:09:00-04:00,ALNY,neutral
63880.0,"Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery",2019-06-21 07:01:00-04:00,ALNY,positive
63881.0,Alnylam Reports Japanese Approval Of ONPATTRO For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy,2019-06-18 08:02:00-04:00,ALNY,positive
63882.0,Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1,2019-06-17 07:22:00-04:00,ALNY,neutral
63883.0,"Alnylam Pharma To Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society Annual Meeting, Congress of the European Academy of Neurology",2019-06-13 08:02:00-04:00,ALNY,neutral
63884.0,Alnylam Completes Rolling Submission Of New Drug Application To FDA For Givosiran For The Treatment Of Acute Hepatic Porphyria,2019-06-05 07:03:00-04:00,ALNY,neutral
63885.0,Alnylam Pharma Reports Dosing Of First Patient in Phase 1 Study of ALN-AGT,2019-05-31 07:00:00-04:00,ALNY,neutral
63886.0,5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential,2019-05-29 12:24:00-04:00,ALNY,neutral
63887.0,"Goldman Sachs Assumes Alnylam Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target $80",2019-05-23 08:58:00-04:00,ALNY,neutral
63888.0,Alnylam Offering By Sanofi Priced At $80.25/Share,2019-05-03 09:40:00-04:00,ALNY,neutral
63889.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Inc. - Common Stock, Raises Price Target to $128",2019-05-02 10:34:00-04:00,ALNY,neutral
63890.0,"Alnylam Pharmaceuticals Q1 EPS $(1.73) Beats $(2.07) Estimate, Sales $33.294M Beat $23.65M Estimate",2019-05-01 08:26:00-04:00,ALNY,neutral
63891.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,ALNY,neutral
63892.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,ALNY,positive
63893.0,"Stifel Nicolaus Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $116",2019-04-15 10:52:00-04:00,ALNY,neutral
63894.0,"Cantor Fitzgerald Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $138",2019-04-15 10:06:00-04:00,ALNY,negative
63895.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $126",2019-04-15 09:11:00-04:00,ALNY,neutral
63896.0,Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study,2019-04-15 07:14:00-04:00,ALNY,positive
63897.0,"Evercore ISI Group Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces $120 Price Target",2019-04-12 07:40:00-04:00,ALNY,neutral
63898.0,"SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $70",2019-04-09 11:26:00-04:00,ALNY,neutral
63899.0,"BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $119",2019-04-09 09:21:00-04:00,ALNY,neutral
63900.0,"Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics",2019-04-08 13:55:00-04:00,ALNY,negative
63901.0,"Alnylam Pharma Shares Resume Trade, Up 0.9%",2019-04-08 07:30:00-04:00,ALNY,positive
63902.0,Alnylam Pharma Shares To Resume Trade At 7:30 a.m. EDT,2019-04-08 07:06:00-04:00,ALNY,positive
63903.0,UPDATE: Alnylam Will Be Eligible For Added $200M In Potential Near-Term Milestones,2019-04-08 07:01:00-04:00,ALNY,neutral
63904.0,"UPDATE: Regeneron Will Invest $800M In Alnylam Through Upfront Cash, Equity Investment",2019-04-08 07:01:00-04:00,ALNY,neutral
63905.0,"Alnylam, Regeneron Report Collaboration To Discover, Develop, Commercialize RNAi Therapeutics Focused On Ocular, Central Nervous System Diseases",2019-04-08 07:00:00-04:00,ALNY,positive
63906.0,Alnylam Pharm Shares Halted News Pending,2019-04-08 06:55:00-04:00,ALNY,positive
63907.0,"Alnylam, Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration",2019-04-08 03:49:00-04:00,ALNY,neutral
63908.0,"Jim Cramer Shares His Thoughts On Mastercard, US Steel And More",2019-04-03 07:48:00-04:00,ALNY,positive
63909.0,58 Biggest Movers From Yesterday,2019-03-07 04:55:00-05:00,ALNY,neutral
63910.0,Hearing Evercore ISI Upgraded Alnylam From In Line To Outperform,2019-03-06 12:56:00-05:00,ALNY,neutral
63911.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-03-06 12:27:00-05:00,ALNY,neutral
63912.0,UPDATE: Alnylam Reports Some Patients Showed Serious Adverse Events,2019-03-06 09:27:00-05:00,ALNY,negative
63913.0,Alnylam Pharmaceuticals shares are trading lower after the company announced that four of its secondary endpoints did not meet the hierarchical threshold for significance in a Phase 3 study of givosiran; many patients also reported serious adverse events.,2019-03-06 09:24:00-05:00,ALNY,negative
63914.0,UPDATE: Anlylam Says Four Of Its Secondary Endpoints Did Not Meet The Hierarchical Threshold For Significance,2019-03-06 07:08:00-05:00,ALNY,positive
63915.0,Alnylam Pharmaceuticals Shares To Resume Trade At 7:30 a.m.,2019-03-06 07:07:00-05:00,ALNY,positive
63916.0,Alnylam Reports Positive ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria Met Primary And Majority Of Secondary Endpoints,2019-03-06 07:03:00-05:00,ALNY,positive
63917.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2019",2019-03-05 09:12:00-05:00,ALNY,positive
63918.0,Morgan Stanley Upgrades Alnylam Pharmaceuticals to Overweight,2019-03-05 06:23:00-05:00,ALNY,negative
63919.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,ALNY,negative
63920.0,UPDATE: Alnylam Sees Topline Phase 3 Readout Data Early 2019,2019-02-06 17:03:00-05:00,ALNY,neutral
63921.0,Alnylam Highlights Publication Of Phase 1 Givosiran In New England Journal Of Medicine,2019-02-06 17:03:00-05:00,ALNY,neutral
63922.0,50 Biggest Movers From Yesterday,2019-01-29 05:17:00-05:00,ALNY,neutral
63923.0,36 Stocks Moving In Monday's Mid-Day Session,2019-01-28 12:50:00-05:00,ALNY,neutral
63924.0,UBS Initiates Coverage On Alnylam Pharmaceuticals with Neutral Rating,2019-01-23 08:24:00-05:00,ALNY,neutral
63925.0,Alnylam Pharma to Collaborate with CAMP4 Therapeutics to Research Rare Diseases,2019-01-23 08:01:00-05:00,ALNY,neutral
63926.0,Alynylam Pharma shares are trading lower after the company priced 5M share stock offering at $77.50/share.,2019-01-15 09:17:00-05:00,ALNY,positive
63927.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-15 08:00:00-05:00,ALNY,neutral
63928.0,Alnylam Pharmaceuticals Prices 5M Share Public Offering of Common Stock @$77.50/Share,2019-01-15 03:34:00-05:00,ALNY,positive
63929.0,Alnylam Pharmaceuticals shares are trading lower after the company announced proposed public offering of 5 million shares of common stock.,2019-01-14 17:06:00-05:00,ALNY,positive
63930.0,Alnylam Pharma Reports Offer Of 5M Shares Of Common Stock,2019-01-14 16:04:00-05:00,ALNY,positive
63931.0,"UPDATE: Guggenheim Reiterates Alnylam Pharmaceuticals As Top Pick As Firm Continues 'to think the Onpattro launch will go well given the existing pool of identified patients and Onpattro's profile vs. competitors'; Reiterates Buy, $105 Target",2019-01-11 09:42:00-05:00,ALNY,positive
